Investment Analysts’ upgrades for Thursday, August 10th:
NMI Holdings (NASDAQ:NMIH) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “NMI Holdings, Inc., through its subsidiaries, provides private mortgage insurance in the United States. NMI Holdings, Inc. is based in Emeryville, California. “
NanoString Technologies (NASDAQ:NSTG) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $17.00 price target on the stock. According to Zacks, “NanoString Technologies, Inc. is engaged in the development, manufacture and sale of life science tools. It provides nCounter Analysis System which supports research and development of clinical applications from basic discovery to the development of future molecular diagnostic tests on a single platform. The company also offers nSolver Analysis software, gene expression panels, miRNA expression assay kits, cancer copy number variation panels, nCounter leukemia fusion gene expression assay kits and human karyotype panels, custom CodeSets and master kits that are ancillary reagents, cartridges, tips and reagent plates to setup and process samples in its instruments. It markets its systems and related consumables to researchers in academic, government and biopharmaceutical laboratories primarily in North America, Europe, the Middle East and the Asia Pacific. NanoString Technologies, Inc. is headquartered in Seattle, Washington. “
Nippon Telegraph & Telephone Corp (NASDAQ:NTTYY) was upgraded by analysts at Zacks Investment Research from a strong sell rating to a hold rating. According to Zacks, “Nippon Telegraph & Telephone provides a variety of telecommunications services, including telephone, telegraph, leased circuits, data communication, terminal equipment sales and other services. The Company provides both local and long distance telephone services within Japan, but it does not provide service in the international markets. “
Novozymes A/S – (NASDAQ:NVZMY) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. They currently have $52.00 target price on the stock. According to Zacks, “Novozymes A/S is primarily engaged in the development, production, and distribution of enzymes. Its business consists of two segments, enzyme business and bio business. The Company’s enzyme business segment offers detergent enzymes that are used in laundry and dishwashing, technical enzymes used in the transformation of starch into different kinds of sugars and have application in leather, textile, and forest product industries, food enzymes used in production of bread, wine, juice, beer, noodles, alcohol, and pasta and feed enzymes used in animal feed. Its bio business segment offers microorganisms that are used in industrial and municipal wastewater treatment, as well as in the cleaning of surfaces such as carpet, concrete, drain lines, and septic tanks in industrial and household applications. It also has application in the Biopharmaceutical ingredients used in pharmaceutical industry. Novozymes A/S is headquartered in Bagsvaerd, Denmark. “
Quanex Building Products Corporation (NYSE:NX) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “QUANEX BUILDING PRODUCTS CORPORATION is a leading manufacturer of engineered materials and components for the U.S. building products market. The Company operates two segments: Engineered Building Products designs proprietary window and door systems and produces fabricated metal, wood and vinyl window and door components, spacer/sealant systems and other products for major window and door manufacturers that primarily serve the residential construction and remodeling markets. Aluminum Sheet Building Products produces coated and mill finish aluminum sheet products for the building and construction market, as well as other capital goods and transportation markets. “
NxStage Medical (NASDAQ:NXTM) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $33.00 price target on the stock. According to Zacks, “NxStage Medical, Inc. is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. “
Obic Co (NASDAQ:OBIIF) was upgraded by analysts at Zacks Investment Research from a sell rating to a buy rating. The firm currently has $51.00 target price on the stock. According to Zacks, “OBIC Co., Ltd provides system integration services, system support services, office automation services, and package software services. It also sells, leases and develops computers, peripherals, related systems and customized software. OBIC Co., Ltd is headquartered in Tokyo, Japan. “
Orion Energy Systems (NASDAQ:OESX) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “ORION ENERGY SYSTEMS, INC. is a leading power technology enterprise that designs, manufactures and implements energy management systems, consisting primarily of high-performance, energy efficient lighting systems, controls and related services, for commercial and industrial customers without compromising their quantity or quality of light. “
Orthofix International N.V. (NASDAQ:OFIX) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $54.00 target price on the stock. According to Zacks, “Orthofix International N.V. is a leading provider of high-value, minimally invasive medical devices for the orthopaedic and trauma markets. Orthofix is well positioned to expand its focus and capitalise on the growing medical acceptance of high technology in orthopaedic treatment and spine repair. The company sells its diverse product line in different countries through its subsidiaries and distribution agreements with leading orthopaedic companies, including Sulzer Medica Group, Sofamor Danek Group, Kendall Healthcare Products and B. Braun. (PRESS RELEASE) “
Universal Display Corporation (NASDAQ:OLED) was upgraded by analysts at Zacks Investment Research from a hold rating to a strong-buy rating. The firm currently has $136.00 price target on the stock. According to Zacks, “Universal Display Corporation is located in the Princeton Crossroads Corporate Center in Ewing, New Jersey, minutes away from its research partner at Princeton University. Universal Display’s state-of-the-art facility is designed to further technology and materials development, technology transfer to manufacturing partners and work with customers to develop OLED products that meet their needs. “
